Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer

Two clinical trials show that trastuzumab emtansine (T-DM1) improves survival compared with other standard treatments for patients with HER2-positive metastatic breast cancer that has progressed after treatment with other HER2-targeted drugs.

Cancer Currents: An NCI Cancer Research Blog